Free Trial

Viking Therapeutics (VKTX) Stock Price, News & Analysis

Viking Therapeutics logo
$34.03 +0.05 (+0.15%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$34.40 +0.37 (+1.09%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Viking Therapeutics Stock (NASDAQ:VKTX)

Key Stats

Today's Range
$33.50
$34.73
50-Day Range
$24.86
$34.42
52-Week Range
$18.92
$81.73
Volume
2.70 million shs
Average Volume
3.96 million shs
Market Capitalization
$3.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$86.92
Consensus Rating
Buy

Company Overview

Viking Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

VKTX MarketRank™: 

Viking Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 396th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Viking Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Viking Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Viking Therapeutics are expected to decrease in the coming year, from ($1.56) to ($2.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viking Therapeutics is -22.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viking Therapeutics is -22.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viking Therapeutics has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Viking Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    25.44% of the outstanding shares of Viking Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Viking Therapeutics has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Viking Therapeutics has recently increased by 88,996.57%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Viking Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viking Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.44% of the outstanding shares of Viking Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Viking Therapeutics has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Viking Therapeutics has recently increased by 88,996.57%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Viking Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Viking Therapeutics this week, compared to 16 articles on an average week.
  • Search Interest

    53 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.
  • MarketBeat Follows

    Only 27 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Viking Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $984,405.00 in company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Viking Therapeutics is held by insiders.

  • Percentage Held by Institutions

    76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Viking Therapeutics' insider trading history.
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Stock News Headlines

[Shocking New Report] U.S. Dollar To Crash?
The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…
See More Headlines

VKTX Stock Analysis - Frequently Asked Questions

Viking Therapeutics' stock was trading at $40.24 at the beginning of the year. Since then, VKTX stock has decreased by 15.4% and is now trading at $34.03.

Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its quarterly earnings results on Wednesday, July, 23rd. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.14. The business's revenue was up NaN% on a year-over-year basis.
Read the conference call transcript
.

Viking Therapeutics (VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Top institutional investors of Viking Therapeutics include Bank of New York Mellon Corp (0.39%), Blair William & Co. IL (0.29%), Simplex Trading LLC and Profit Investment Management LLC (0.10%). Insiders that own company stock include Brian Lian, Marianna Mancini, Greg Zante, Lawson Macartney, Charles A Rowland Jr, J Matthew Singleton and Sarah Kathryn Rouan.
View institutional ownership trends
.

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viking Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Invesco QQQ (QQQ), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
7/23/2025
Today
8/05/2025
Next Earnings (Estimated)
10/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VKTX
CIK
1607678
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$138.00
Low Price Target
$30.00
Potential Upside/Downside
+155.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$109.96 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-19.98%
Return on Assets
-19.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
25.86
Quick Ratio
25.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.90 per share
Price / Book
4.31

Miscellaneous

Outstanding Shares
112,440,000
Free Float
107,835,000
Market Cap
$3.83 billion
Optionable
Optionable
Beta
0.67

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:VKTX) was last updated on 8/6/2025 by MarketBeat.com Staff
From Our Partners